Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome

Clinical and Experimental Immunology

Volumn 131, Issue 2, 2003, Pages 217-224

  Gomez S A ^a   Fernandez G C ^a   Vanzulli, S ^a   Dran, G ^b   Rubel, C ^a   Berki, T ^b   Isturiz, M A ^a   Palermo, Marina S ^a,b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Glucocorticoid receptors; Glucocorticoids; HUS; Neutrophils; Stx2

Indexed keywords

BACTERIAL TOXIN; CORTICOSTERONE; CYTOKINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1BETA; SHIGA TOXIN; TUMOR NECROSIS FACTOR ALPHA; VEROTOXIN 2;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAM NEGATIVE INFECTION; HEMOLYTIC UREMIC SYNDROME; IMMUNE RESPONSE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

EID: 0037313994     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02057.x     Document Type: Article

References (51)

1. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int 1995; 47:2-19.
2. Koster F, Boonpucknavig V, Sujaho S, Gilman R, Rahaman M. Renal histopathology in the hemolytic uremic syndrome following shigellosis. Clin Nephrol 1984; 21:126-33.
3. Arbus GS. Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome. Kidney Int 1997; 58: S91-6.
4. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151:775-82.
5. Keusch GT, Acheson DWK. Thrombotic thrombocytopenic purpura associated with shiga toxins. Semin Hematol 1997; 34:106-16.
6. Paton JC, Paton AW. Pathogenesis and diagnosis of shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11:450-79.
7. Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 2001; 183:435-43.
8. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in shiga toxin receptors and responses. J Biol Chem 1993; 268:15484-8.
9. Fernández GC, Rubel C, Dran G, Gomez S, Isturiz MA, Palermo MS. Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome. Clin Immunol 2000; 95:227-34.
10. Taylor FB Jr, Tesh VL, DeBault L et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999; 154:1285-99.
11. Wadolkowski EA, Burris JA, O'Brien AD. Mouse model for colonization and disease caused by enterohemorragic Escherichia coli O157:H7. Infect Immun 1990; 58: 2438-45.
12. Francis DH, Moxley RA, Andraos CY. Edema disease-like brain lesions in gnotobiotic piglets infected with Escherichia coli serotype O157:H7. Infect Immun 1989; 57: 1339-42.
13. Barret TJ, Potter ME, Wachsmuth K. Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect Immun 1989; 57:3434-7.
14. Harel Y, Silva M, Giroir B, Weinberg A, Cleary TB, Beutler B. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. J Clin Invest 1993; 92:2110-6.
15. Palermo MS, Alves Rosa MF, Van Rooijen N, Isturiz MA. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Clin Exp Immunol 1999; 116:462-7.
16. Forsyth KD, Simpson AC, Fitzpatrick MM, Barratt TM, Levinsky RJ. Neutrophil mediated endothelial injury in haemolytic uraemic syndrome. Lancet 1989; 2:411-4.
17. Te Loo DMWM, Monnens LAH, van der Velden TJAM et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95:3396-402.
18. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev 1982; 65:133-53.
19. Kapcala LP, Chautard T, Reskay RL. The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious and inflammatory stress. Ann NY Acad Sci 1995; 771:419-37.
20. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol Today 1985; 15:504-11.
21. Miller AH, Spencer RL, Pearce BD et al. Effects of viral infection on corticosterone secretion and glucocorticoid receptor binding in immune tissues. Psychoneuroendocrinology 1997; 22:455-74.
22. Del Rey A, Klusman I, Besedovsky HO. Cytokines mediate protective stimulation of glucocorticoid output during autoimmunity: involvement of IL-1. Am J Physiol 1998; 275:R1146-51.
23. MacPhee IAM, Antoni FA, Mason WD. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 1989; 169:431-45.
24. Sternberg EM, Hill JM, Chrousos GP et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis susceptible Lewis rats. Proc Natl Acad Sci USA 1989; 86:2374-8.
25. Middelveld RJ, Wanecek M, Bergman D, Weitzberg E, Alving K. Effect of cortisol-synthesis inhibition on endotoxin-induced porcine acute lung injury, shock and nitric oxide production. Shock 1999; 12:382-90.
26. Berki T, Kumánovics GK, Kumánovics A, Falus A, Újhelyi E, Németh P. Production and flow cytometric application of a monoclonal anti-glucocorticoid receptor antibody. J Immunol Meth 1998; 214:19-27.
27. Duner KI. A new kinetic single stage Limulus amoebocyte lysate method for the detection of endotoxin in water and plasma. J Biochem Biophys Meth 1993; 26:131-42.
28. Vinson RB, Carroll JL, Pret SB. Mechanism of suppressed neutrophil mobilization in a mouse model for binge drinking: role of glucocorticoids. Am J Physiol 1998; 275:R1049-57.
29. Palermo MS, Rubel C, Alves Rosa F et al. Pretreatment of mice with LPS or IL-1β exerts opposite effects on Shiga-toxin-2 lethality. Clin Exp Immunol 1999; 119:77-83.
30. Coligan J, Knisblek A, Margulies D, Shevach E, Warren S. In vitro assays for mouse lymphocyte function. In: Coligan J, Knisblek A, Margulies D et al., eds. Current protocols in mununology. National Institute of Health. USA: Wiley & Sons Inc., 1994:3.20.3-4.
31. Knapp W, Majdic O, Strobl H. Flow cytometric analysis of cell surface and intracellular antigens in leukemia diagnosis. Cytometry 1994; 18:187-98.
32. Miller AH, Spencer RL, Pearce BD et al. Glucocorticoid receptors are differentially expressed in the cells and tissues of the immune system. Cell Immunol 1998; 186:45-54.
33. Baybutt HN, Holsboer NJ. Inhibition of macrophage differentiation and function by cortisol. Endocrinology 1990; 127:476-80.
34. Zanker B, Walz G, Wleder J, Strom TB. Evidence that glucocorticoids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990; 49:183-5.
35. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982; 129:1803-5.
36. Fantuzi G, Di Santo E, Sacco S, Benigni F, Ghezzi P. Role of hypothalamus-pituitary-adrenal axis in the regulation of TNF production in mice. J Immunol 1995; 155:3552-5.
37. Youssef P, Roberts-Thomson P, Ahern M, Smith M. Pulse methyl-prednisolone in rheumatoid arthritis: effects on peripheral blood and synovial fluid neutrophil surface phenotype. J Rheumatol 1995; 22:2065-71.
38. Goulding NJ, Euzger HS, Butt SK, Perretti M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm Res 1998; 47:S158-65.
39. Yazawa H, Kato T, Nakata T, Sendo F. Glucocorticoid hormone suppression of human neutrophil-mediated tumor cell cytostasis. Int J Cancer 1999; 81:74-80.
40. Foster GH, Armstrong CS, Sakiri R, Tesh VL. Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases. Infect Immun 2000; 68:5183-9.
41. Bertini R, Bianchi M, Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med 1988; 167:1708-12.
42. Butler LD, Layman NK, Riedl PE et al. Neuroendocrine regulation of in vivo cytokine production and effects: I. In vivo regulatory networks involving the neuroendocrine system, interleukin-1 and tumor necrosis factor-alpha. J Neuroimmunol 1989; 24:143-53.
43. McEwen BS, Biron CA, Brunson KW et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Rev 1997; 23:79-133.
44. Vanderbilt JN, Miesfield R, Maler BA, Yamamoto KR. Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol Endocrinol 1987; 1:68-74.
45. Salkowski AA, Vogel SN. Lipopolysaccharide increases glucocorticoid receptor expression in murine macrophages. A posible mechanism for glucocorticoid-mediated suppression of endotoxicity. J Immunol 1992; 149:4041-7.
46. Danielsen M, Stallcup MR. Down-regulation of glucocorticoid receptors in mouse lymphoma cell variants. Mol Cell Biol 1984; 4:449-53.
47. Torsteinsdottir I, Arvidson NG, Hallgren R, Hakansson L. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effects of glucocorticoids. Scand J Immunol 1999; 50:433-9.
48. Filep JG, Delalandre A, Payette Y, Foldes-Filep E. Glucocorticoid receptor regulates expression of L-selectin and CD11/CD18 on human neutrophils. Circulation 1997; 97:2279-81.
49. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weismann G. A mechanism for the antiinflamatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992; 89:9991-5.
50. Leech M, Hutchinson P, Holsworth SR, Morand EF. Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clin Exp Immunol 1998; 112:383-8.
51. Besedovsky HO, Del Rey A. Immune-neuro-endocrine interaction: facts and hypotheses. Endocr Rev 1996; 17:64-102.